Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system to maximize viral clearance.
Cidara’s Cloudbreak antiviral platform is a fundamentally new approach to treating and preventing viral infections. By applying the principles of immuno-oncology to infectious disease, Cidara is creating a new generation of antivirals that stably couple a potent antiviral targeting domain, a small molecule or a peptide, to an effector domain, a proprietary variant of a human antibody fragment (Fc). These long-acting, bispecific AVCs are designed to directly inhibit viral proliferation while simultaneously directing immune-mediated clearance of the virus. The two distinct and complementary mechanisms are designed to maximize antiviral activity of AVCs.
Development candidate AVCs, CD377 and CD388, are being studied for universal prevention and treatment of influenza. Cidara is also advancing preclinical and discovery programs to target additional life-threatening viruses, including RSV, HIV and SARS-CoV-2.